AU609120B2 - Use of ODC inhibitors, dacarbazine, and interferon in the treatment of malignant melanoma - Google Patents

Use of ODC inhibitors, dacarbazine, and interferon in the treatment of malignant melanoma Download PDF

Info

Publication number
AU609120B2
AU609120B2 AU15023/88A AU1502388A AU609120B2 AU 609120 B2 AU609120 B2 AU 609120B2 AU 15023/88 A AU15023/88 A AU 15023/88A AU 1502388 A AU1502388 A AU 1502388A AU 609120 B2 AU609120 B2 AU 609120B2
Authority
AU
Australia
Prior art keywords
acceptable salt
interferon
ornithine
treatment
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU15023/88A
Other languages
English (en)
Other versions
AU1502388A (en
Inventor
Sai P. Sunkara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Publication of AU1502388A publication Critical patent/AU1502388A/en
Application granted granted Critical
Publication of AU609120B2 publication Critical patent/AU609120B2/en
Assigned to MERRELL PHARMACEUTICALS INC. reassignment MERRELL PHARMACEUTICALS INC. Request to Amend Deed and Register Assignors: MERRELL DOW PHARMACEUTICALS INC.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU15023/88A 1987-04-23 1988-04-21 Use of ODC inhibitors, dacarbazine, and interferon in the treatment of malignant melanoma Ceased AU609120B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4189187A 1987-04-23 1987-04-23
US041891 1987-04-23

Publications (2)

Publication Number Publication Date
AU1502388A AU1502388A (en) 1988-10-27
AU609120B2 true AU609120B2 (en) 1991-04-26

Family

ID=21918900

Family Applications (1)

Application Number Title Priority Date Filing Date
AU15023/88A Ceased AU609120B2 (en) 1987-04-23 1988-04-21 Use of ODC inhibitors, dacarbazine, and interferon in the treatment of malignant melanoma

Country Status (11)

Country Link
EP (1) EP0288055B1 (enExample)
JP (1) JPS63280019A (enExample)
KR (1) KR880012239A (enExample)
AT (1) ATE78174T1 (enExample)
AU (1) AU609120B2 (enExample)
DE (1) DE3872749T2 (enExample)
DK (1) DK167905B1 (enExample)
ES (1) ES2051788T3 (enExample)
GR (1) GR3005553T3 (enExample)
IE (1) IE61498B1 (enExample)
ZA (1) ZA882719B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0369944A1 (de) * 1988-11-18 1990-05-23 Ciba-Geigy Ag Substituierte Oxadiaminobutane
IL97759A0 (en) * 1990-04-11 1992-06-21 Ciba Geigy Ag Hydroxylamine compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4999072A (en) * 1987-10-19 1991-03-12 Milliken Research Corporation Method of making an insole product

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499072A (en) * 1982-11-29 1985-02-12 Merrell Dow Pharmaceuticals Inc. Process for treating diseases with ODC inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4999072A (en) * 1987-10-19 1991-03-12 Milliken Research Corporation Method of making an insole product

Also Published As

Publication number Publication date
GR3005553T3 (enExample) 1993-06-07
IE881221L (en) 1988-10-23
DK222988D0 (da) 1988-04-22
IE61498B1 (en) 1994-11-02
EP0288055B1 (en) 1992-07-15
ZA882719B (en) 1988-10-17
EP0288055A1 (en) 1988-10-26
AU1502388A (en) 1988-10-27
DK222988A (da) 1988-10-24
DE3872749D1 (de) 1992-08-20
DK167905B1 (da) 1994-01-03
KR880012239A (ko) 1988-11-26
ATE78174T1 (de) 1992-08-15
DE3872749T2 (de) 1992-12-03
ES2051788T3 (es) 1994-07-01
JPS63280019A (ja) 1988-11-17

Similar Documents

Publication Publication Date Title
US4499072A (en) Process for treating diseases with ODC inhibitors
US4693995A (en) Pharmaceutical composition for the treatment of acute myocardial ischemia
Wildhirt et al. Involvement of inducible nitric oxide synthase in the inflammatory process of myocardial infarction
JP4991107B2 (ja) コンブレタスタチンおよび抗癌剤からなる組成物
US5696153A (en) Therapeutic regimen for treating patients
EP0923371B1 (en) Pharmaceutical compositions comprising tyrphostins
Kim et al. Radiosensitization of Meth-A fibrosarcoma in mice by lonidamine
JP2005530786A (ja) 心損傷の処置のためのピロロキノリンキノンおよびその使用方法
US9084812B2 (en) Composition useful for the prevention or reduction of the progression of prostate cancer
RU2730998C2 (ru) Композиции форболовых эфиров и способы их применения для лечения или уменьшения продолжительности цитопении
BE905198A (nl) Farmaceutische preparaten met vaatverwijdende en anti-anoxische werking.
JP2706371B2 (ja) 癌治療用補助剤及びそれを用いたキット
EP0288055B1 (en) Use of odc inhibitors, dacarbazine, and interferon, in the treatment of malignant melanoma
JPH0681724B2 (ja) 癌転移と増殖の予防および治療用組成物
WO1997002822A1 (en) Drug for ameliorating brain diseases
EP0248217B1 (en) Use of ornithine decarboxylase inhibitor for preparing a medicament for use in the treatment, in conjuction with lak cells and interleukin-2, of tumors
US3326761A (en) 6-demethyl-6-deoxytetracycline, anti-tumor antibiotic
Schultz et al. Potentiation of nonspecific immunotherapy of experimental lung metastases by indomethacin
US5312833A (en) Method of inhibiting tumor growth using xanthocillin X dimethylether
JP2007536256A (ja) 心臓損傷の処置のためのピロロキノリンキノン薬およびその使用方法
WO1991014432A1 (en) Supportive use
KR20020060148A (ko) 마크롤라이드 화합물의 신규한 용도
CA1256031A (en) Pharmaceutical compositions containing diltiazem and alfuzosin
PH26698A (en) Method of potentiating natural killer cell activity
JP2001151700A (ja) リンパ系腫瘍性疾患治療剤

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: MERRELL PHARMACEUTICALS INC.

Free format text: FORMER NAME WAS: MERRELL DOW PHARMACEUTICALS INC.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired